Rheumatology International

, Volume 26, Issue 2, pp 137–141 | Cite as

The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis

  • Gert E. Hein
  • Markus Köhler
  • Peter Oelzner
  • Günter Stein
  • Sybille Franke
Original Article



Oxidative stress and inflammatory processes accelerate the formation of advanced glycation end products (AGE), e.g. of pentosidine. The aim of this study was to investigate the relationships between levels of pentosidine in serum and synovial fluid, proinflammatory cytokines, other markers of inflammatory activity, and the state of radiologically visible bone destruction in patients with rheumatoid arthritis (RA).


One hundred thirty-three nondiabetic RA patients and 56 age-matched, healthy subjects were included. Serum and synovial fluid pentosidine, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and rheumatoid factor levels were determined. In 30 patients, the proinflammatory cytokines interleukin (IL)-1β, IL-6, and TNF-α and the soluble receptors sIL-2R, sIL-6R, sTNF-α, and RI/RII were also measured.


Serum levels of pentosidine were on average significantly higher in RA patients than in healthy subjects and correlated significantly to ESR, CRP, and serum levels of IL-6. Serum and synovial fluid pentosidine did not show any differences. Rheumatoid factor-positive RA patients had higher pentosidine levels in the synovial fluid than rheumatoid factor-negative patients. Correlations could not be found between pentosidine and the other cytokines or cytokine receptors measured.


The binding of AGE on cell receptors induces activation of nuclear factor kappa B, resulting in enhanced synthesis of proinflammatory cytokines. Moreover, AGE generation may also lead to the formation of new, immunologically relevant epitopes at synovial proteins. Both mechanisms could contribute to initiation and perpetuation of the inflammatory and destructive processes in RA.


Advanced glycation end products Inflammatory markers Pentosidine 


  1. 1.
    Zvaifler NJ, Firestein GS (1994) Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 37:783–789PubMedGoogle Scholar
  2. 2.
    Kinne RW, Palombo-Kinne E, Emmrich F (1995) Activation of synovial fibroblasts in rheumatoid arthritis. Ann Rheum Dis 54:501–504Google Scholar
  3. 3.
    Panayi GS, Lanchbury JS, Kingsley GH (1992) The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 35:729–734PubMedGoogle Scholar
  4. 4.
    Fox DA (1997) The role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 40:598–609PubMedGoogle Scholar
  5. 5.
    Edmonds SE, Ellis G, Gaffney K, Archer J, Blake DR (1995) Hypoxia and the rheumatoid joint: immunological and therapeutic implications. Scand J Rheumatol 24 [Suppl 101]:163–168Google Scholar
  6. 6.
    Vlassara H, Palace MR (2002) Diabetes and advanced glycation end products. J Intern Med 251:87–101CrossRefPubMedGoogle Scholar
  7. 7.
    Vlassara H (2001) The AGE-receptor in the pathogenesis of diabetic complications. Diabetes Metab Res Rev 17:436–443CrossRefPubMedGoogle Scholar
  8. 8.
    Hofmann MA, Schiekofer S, Isermann B, Treusch A, Kanitz M, Klevesath MS, Joswing M, Morcos M, Weiss T, Borcea V, Khalet AM, Amiral J, Tritschler H, Wahl P, Ziegler R, Ritz E, Bierhaus A, Nawroth P (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy demonstrated increased activation of the oxidative-stress sensitive transcription NF-κB. Diabetologia 42:222–232CrossRefPubMedGoogle Scholar
  9. 9.
    Daoud S, Schinzel R, Neumann A, Loske C, Fraccarollo D, Diez C, Simm A (2001) Advanced glycation end products: activator of cardiac remodeling in primary fibroblasts from adult rat heart. Mol Med 7:543–551PubMedGoogle Scholar
  10. 10.
    Takahashi M, Suzuki M, Kushida K, Miyamoto S, Inoue T (1997) Relationship between pentosidine levels in serum and urine and activity in rheumatoid arthritis. Br J Rheumatol 36:637–642CrossRefPubMedGoogle Scholar
  11. 11.
    Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K (1998) Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relation with inflammatory markers. Biochem Biophys Res Commun 244:45–49CrossRefPubMedGoogle Scholar
  12. 12.
    Drinda S, Franke S, Canet CC, Petrow P, Bräuer R, Hüttich C, Stein G, Hein G (2002) Identification of Ne-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis. Ann Rheum Dis 61:488–492CrossRefPubMedGoogle Scholar
  13. 13.
    Drinda S Franke S, Rüster M, Petrow P, Pullig O, Stein G, Hein G (2004) Identification of the receptor of AGE (advanced glycation end products) in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int (accepted for publication)Google Scholar
  14. 14.
    Hein G, Wiegand R, Lehmann G, Stein G, Franke S (2003) Advanced glycation end-products pentosidine and Ne-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology 42:1242–1246CrossRefPubMedGoogle Scholar
  15. 15.
    Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, Taketomie S (1997) Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol 8:260–270PubMedGoogle Scholar
  16. 16.
    Hein G, Franke S (2002) Are advanced glycation end-product-modified proteins of pathogenetic importance in fibromyalgia? Rheumatology 41:1163–1167Google Scholar
  17. 17.
    Miyata T, Ueda Y, Shinzato T et al (1996) Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 7:1198–1206PubMedGoogle Scholar
  18. 18.
    Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implication for the induction of oxidative stress and cellular dysfunction in the pathogenesis of vascular lesions. Atheroscler Thromb 14:1521–1528Google Scholar
  19. 19.
    Nawroth PP, Bierhaus A, Vogel GE, Hofmann MA, Zumbach M, Wahl P, Ziegler R (1999) Nonenzymatic glycation and oxidative stress in chronic diseases and diabetes mellitus [German]. Med Klin 94:29–38Google Scholar
  20. 20.
    Makarov SS (2001) NF-kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia and tissue destruction. Arthritis Res 3:200–206CrossRefPubMedGoogle Scholar
  21. 21.
    Handel ML, McMorrow LB, Gravallese EM (1995) Nuclear factor-kappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum 38:1762–1770PubMedGoogle Scholar
  22. 22.
    Georganas C, Liu H, Perlman H, Hoffmann A, Thimmapaya B, Pope RM (2000) Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun. J Immunol 165:7199–7206Google Scholar
  23. 23.
    Yoshida S, Kato T, Sakurada S et al (1999) Inhibition of IL-6 and IL-8 from cultured rheumatoid synovial fibroblasts by treatment with aurothioglucose. Int Immunol 11:151–158Google Scholar
  24. 24.
    Sakurada S, Kato T, Okamoto T (1996) Induction of cytokines and ICAM-1 by proinflammatory cytokines in primary rheumatoid synovial fibroblasts and inhibition by N-acetyl-L-cysteine and aspirin. Int Immunol 8:1483–1493Google Scholar
  25. 25.
    Tomita T, Takano H, Tomota N et al (2000) Transcription factor decoy for NFkB inhibits cytokine and adhesion molecule expression in synovial cells derived from rheumatoid arthritis. Rheumatology 39:749–757CrossRefPubMedGoogle Scholar
  26. 26.
    Hofbauer LC, Heufelder AE (2001) The role of osteoprotegerin and receptor activator of nuclear factor kB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253–259CrossRefPubMedGoogle Scholar
  27. 27.
    Li P, Sanz I, O’Keefe RJ, Schwarz EM (2000) NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol 164:5990–5997Google Scholar
  28. 28.
    Bond M, Baker AH, Newby AC (1999) Nuclear factor kappa B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 264:561–567CrossRefPubMedGoogle Scholar
  29. 29.
    Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor κB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243–253CrossRefPubMedGoogle Scholar
  30. 30.
    Takagi M, Kasayama S, Yamamoto T et al (1997) Advanced glycation endproducts stimulate interleukin-6 production by human bone derived cells. J Bone Miner Res 12:439–446PubMedGoogle Scholar
  31. 31.
    Yang C, Acil Y, Muller PK (1994) An unique antigenic determinant on collagen II closely associated with age related abnormal modification. Biochem Biophys Res Commun 16:1641–1649CrossRefGoogle Scholar
  32. 32.
    Michaelsson E, Malmstrom V, Reis S, Engstrom A, Burkhardt H, Holmdahl R (1994) T cell recognition of carbohydrates on type II collagen. J Exp Med 180:745–749CrossRefPubMedGoogle Scholar
  33. 33.
    Charriere G, Hartmann DJ, Vignon E, Ronziere MC, Herbage D, Ville G (1988) Antibodies to types I, II, IX and XI collagen in the serum of patients with rheumatic diseases. Arthritis Rheum 31:325–332PubMedGoogle Scholar
  34. 34.
    Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P (1996) Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 39:1720–1727PubMedGoogle Scholar
  35. 35.
    Terato K, Shimozuru Y, Katayama K, Takemitsu Y, Yamashita I, Miyatsu M, Fujii K, Sagara M, Kobayashi S, Goto M et al (1990) Specificity of antibodies to type II collagen in rheumatoid arthritis. Arthritis Rheum 33:1493–1500PubMedGoogle Scholar
  36. 36.
    Wooley PH, Luthra HS, Singh SK, Huse AR, Stuart JM, David CS (1984) Passive transfer of arthritis to mice by injection of human anti-type II collagen antibody. Mayo Clin Proc 59:737–743PubMedGoogle Scholar
  37. 37.
    Tai AW, Newkirk MM (2000) An autoantibody targeting glycated IgG is associated with elevated serum immune complexes in rheumatoid arthritis (RA). Clin Exp Immunol 120:188–193CrossRefPubMedGoogle Scholar
  38. 38.
    Ligier S, Fortin PR, Newkirk MM (1998) A new antibody in rheumatoid arthritis targeting glycated IgG: IgM anti-IgG-AGE. Br J Rheumatol 37:1307–1314CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Gert E. Hein
    • 1
  • Markus Köhler
    • 1
  • Peter Oelzner
    • 1
  • Günter Stein
    • 1
  • Sybille Franke
    • 1
  1. 1.Rheumatology and Osteology, Department of Internal Medicine IIIFriedrich Schiller University of JenaJenaGermany

Personalised recommendations